Vivos Therapeutics (VVOS) Equity Average (2021 - 2025)
Historic Equity Average for Vivos Therapeutics (VVOS) over the last 5 years, with Q3 2025 value amounting to $3.6 million.
- Vivos Therapeutics' Equity Average fell 4922.21% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 4922.21%. This contributed to the annual value of $4.2 million for FY2024, which is 6049.5% up from last year.
- Latest data reveals that Vivos Therapeutics reported Equity Average of $3.6 million as of Q3 2025, which was down 4922.21% from $4.5 million recorded in Q2 2025.
- In the past 5 years, Vivos Therapeutics' Equity Average registered a high of $34.5 million during Q3 2021, and its lowest value of $228500.0 during Q4 2023.
- In the last 5 years, Vivos Therapeutics' Equity Average had a median value of $7.0 million in 2024 and averaged $11.1 million.
- Per our database at Business Quant, Vivos Therapeutics' Equity Average tumbled by 9688.18% in 2023 and then surged by 331772.43% in 2024.
- Quarter analysis of 5 years shows Vivos Therapeutics' Equity Average stood at $29.0 million in 2021, then plummeted by 74.73% to $7.3 million in 2022, then crashed by 96.88% to $228500.0 in 2023, then soared by 3317.72% to $7.8 million in 2024, then plummeted by 54.45% to $3.6 million in 2025.
- Its last three reported values are $3.6 million in Q3 2025, $4.5 million for Q2 2025, and $6.2 million during Q1 2025.